PRME - Prime Medicine, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $7.00 DETAILS

Stock News

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.

Jul 09, 2026 06:22 AM • seekingalpha.com

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).

Jul 08, 2026 09:29 AM • benzinga.com

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties' 2019 Collaboration and License Agreement (Agreement).

Jul 08, 2026 04:00 AM • globenewswire.com

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review -- -- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations -- CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell therapy for the treatment of p47phox-deficient chronic granulomatous disease (CGD).

Jun 22, 2026 04:00 AM • globenewswire.com

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

Jun 18, 2026 04:00 AM • globenewswire.com

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.

Jun 15, 2026 12:10 PM • fool.com

Prime Medicine's Prime Editing Is Worth The Risk

Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it's now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD.

Jun 13, 2026 12:51 AM • seekingalpha.com

Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”).

Jun 12, 2026 02:30 PM • globenewswire.com

Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Jun 10, 2026 11:12 AM • seekingalpha.com

Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jun 05, 2026 12:12 PM • seekingalpha.com

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D.

Jun 03, 2026 04:00 AM • globenewswire.com

Prime Medicine to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D.

May 28, 2026 04:00 AM • globenewswire.com

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.4 per share a year ago.

May 07, 2026 08:16 AM • zacks.com

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.

May 07, 2026 04:00 AM • globenewswire.com

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO).

Apr 16, 2026 04:00 AM • globenewswire.com

Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units

MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a non-brokered private placement (the “Private Placement”) of a minimum of 10 units (each, a “Unit”) and a maximum of 16 Units at a price of $250,000 per Unit, for minimum and maximum gross proceeds of $2,500,000 and $4,000,000, respectively.

Apr 14, 2026 04:28 PM • globenewswire.com

Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Risk and Volatility Prime Medicine has a

Mar 24, 2026 10:46 PM • defenseworld.net

Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Earnings and Valuation This table compares Athira

Mar 24, 2026 09:10 PM • defenseworld.net

Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of

Mar 19, 2026 09:17 PM • defenseworld.net

Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review

Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Earnings and Valuation This table compares Athira

Mar 18, 2026 10:14 PM • defenseworld.net